Teewinot Life Sciences Corporation, a Global Leader in Pharmaceutical Cannabinoid Production, Secures $12.3M Series B Round

Published Monday, May 1, 2017

NEW YORK and TAMPA, Fla., May 1, 2017 /PRNewswire/ -- Teewinot Life Sciences Corporation (Teewinot), an industry leader in discovery, development and commercialization of cannabinoid-based therapeutics and the global leader in the biocatalytic production of cannabinoids, announced today that it has closed it's $12.3 million Series B round led by Tuatara Capital, a New York based private equity fund focused on investments in cannabis-related companies.  With the original Series B target having been set at $10 million, the funds raised were nearly 25 percent oversubscribed.  Tuatara Capital also led Teewinot's $7 million Series A round in December 2015.

Learn more>>>